texas oncology more breakthroughs. more victories
I am a: Patient | Caregiver | Refering Physician
Some of our cancer centers may have important notifications found on the location page. View More Important Notifications x

Andrew Robert Whiteley, M.D.

Andrew Robert Whiteley, M.D. Photo

Provider Type: Physician

Specialties:
Board Certifications:
  • Internal Medicine
  • Medical Oncology
Spoken Language: English

Downloads

Education

  • Fellowship in Oncology
    Baylor University Medical Center, Dallas, TX
  • Residency in Internal Medicine
    Baylor University Medical Center, Dallas, TX
  • Medical Doctorate
    University of Arkansas for Medical Sciences, Little Rock, AR

Accolades & Memberships

  • American Society of Clinical Oncology
  • Texas Medical Association

Why a patient should choose treatment at your practice?

We have a large sub-specialized practice that has allowed me to focus solely on the treatment of hematologic disorders and hematologic malignancies. We have a thriving clinical trials program for myriad malignancies.  Our staff are friendly and caring.

What is your personal philosophy around patient care?

I pride myself on communicating well with patients. You shouldn’t have to have an advanced degree to understand your medical problems and treatment options. I educate my patients and provide my recommendations, and want them to feel empowered to share in the decision-making process about what is best for their health.

Publications

  • Phase  1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

    American Society of Hematology, 2020

  • Targeting LIF-Mediated Paracrine Interaction for Pancreatic Cancer Therapy and Monitoring

    Proceedings (Baylor University Medical Center), 2019

  • An Unusual Presentation of an Uncommon Lymphoma, Hepatosplenic T-Cell Lymphoma

    Baylor University Medical Center Proceedings, 2019

  • Phase  1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing ≥ 3 Prior TKI Therapies: Initial Safety and Efficacy

    Annual Meeting of the American Society of Hematology, 2019

  • Early Stage IgD Multiple Myeloma in a 50-Year-Old Man

    Baylor University Medical Center Proceedings, 2019

Show all Publications
  • A Pilot, Non-Randomized Evaluation of the Safety of Anakinra Plus FOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma

    American Society of Clinical Oncology Annual Meeting Abstract, 2016

  • EGFR Fusions As Novel Therapeutic Targets in Lung Cancer

    Cancer Discovery, 2016

Research Interest

Dr. Whiteley has a research interest in leukemia, lymphoma, and myeloma.

Other Information

Dr. Whiteley recently welcomed his daughter as the first addition to his family and enjoys biking, traveling, sports, good food, and spending time with family and friends.